SpectraCure
1,738 SEK -4,92%1 investor følger denne virksomhed
SpectraCure is a medical technology company The company specializes in the research and development of medical technology systems used to treat prostate cancer. The cancer treatments are based on proprietary systems that emit laser light sources and photoreactive drugs, a treatment methodology used for internally solid tumors of various types. The company operates in the Nordic market. The head office is located in Lund.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
SPEC
Daglig lav / høj pris
1,606 / 1,828
SEK
Markedsværdi
168,81 mio. SEK
Aktieomsætning
192,92 t SEK
Volumen
110 t
Finanskalender
Delårsrapport
14.11.2024
Årsrapport
20.02.2025
Delårsrapport
15.05.2025
Delårsrapport
15.08.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Masoud Khayyami | 10,0 % | 10,0 % |
Avanza Pension | 5,0 % | 5,0 % |
Cardeon Futuring Fincance AB | 3,2 % | 3,2 % |
Jens Nilsen | 2,5 % | 2,5 % |
Swedbank Försäkring | 1,8 % | 1,8 % |
Nordnet Pensionsförsäkring | 1,8 % | 1,8 % |
Jörgen Wennberg | 1,4 % | 1,4 % |
Pension Futur | 1,2 % | 1,2 % |
Dan Persson | 0,6 % | 0,6 % |
Olle Persson | 0,5 % | 0,5 % |
ViserAlle indholdstyper
A well-accomplished annual audit in accordance with ISO 13485:2016
Expert group comments on results of ongoing study
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools